Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
Stocks · News reference
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday
Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
8-K filing — ADC Therapeutics SA (ADCT)
Filed: 2026-08-13 AccNo: 0000950103-26-012287 Size: 33 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
ADC Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Shares of semiconductor and chip companies are trading higher. The broader industry may be rallying alongside memory and storage-related peers.
Cerebras Systems Stock Climbs Wednesday: What's Going On?
Shares of Cerebras Systems are rebounding Wednesday morning, recovering Tuesday's losses as traders absorb a 14.6 million share post-IPO lockup expiration alongside new international data center momentum.